Genezen reports that the company became the first CDMO to license CSL’s Cytegrity™ cell line production system that was designed for the production of lentiviral vectors (LVVs). “We have significant, ...
CSL is one of three tier one plasma therapy companies who benefit from an oligopoly in this highly consolidated market. All the players are vertically integrated as plasma sourcing is the most ...
CSL shares are down roughly 40% since acquiring Vifor in August 2022, an iron deficiency and kidney disease business and the largest acquisition in its history. However, several other factors have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results